Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.4 GBX | -6.05% | -8.39% | -65.32% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-65.32% | 195M | - | ||
+11.91% | 114B | B+ | ||
+11.60% | 105B | B+ | ||
-4.68% | 23.83B | B+ | ||
-0.82% | 21.73B | B | ||
-10.12% | 18.1B | A- | ||
-42.12% | 16.34B | A- | ||
-17.47% | 16.13B | B | ||
+2.77% | 13.75B | C+ | ||
+34.58% | 11.76B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AVCT Stock
- Ratings Avacta Group Plc